Unsolved issues in CLL biology and management

被引：27

作者：

Dighiero, G ^{[1
]}

机构：

[1] Inst Pasteur, Unite Immunohematol & Immunopathol, F-75015 Paris, France

来源：

LEUKEMIA | 2003年 / 17卷 / 12期

关键词：

D O I：

10.1038/sj.leu.2403154

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：2385 / 2391

页数：7

共 96 条

[1]

[Anonymous], 1990, Blood, V75, P1422

[2]

[Anonymous], 1999, J Natl Cancer Inst, V91, P861

[3]

BINET JH, 1986, LANCET, V1, P1346

[4]

BINET JL, 1990, BRIT J HAEMATOL, V76, P45

[5]

BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO

[6]

2-V

[7]

BINET JL, 1987, SEMIN HEMATOL, V24, P275

[8]

BORCHE L, 1990, BLOOD, V76, P562

[9] CHRONIC LYMPHOCYTIC LEUKEMIC (CLL) CELLS SECRETE MULTISPECIFIC AUTOANTIBODIES [J].

BROKER, BM ;

KLAJMAN, A ;

YOUINOU, P ;

JOUQUAN, J ;

WORMAN, CP ;

MURPHY, J ;

MACKENZIE, L ;

QUARTEYPAPAFIO, R ;

BLASCHEK, M ;

COLLINS, P ;

LAL, S ;

LYDYARD, PM .

JOURNAL OF AUTOIMMUNITY, 1988, 1 (05) :469-481

[10] Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].

Byrd, JC ;

Peterson, BL ;

Morrison, VA ;

Park, K ;

Jacobson, R ;

Hoke, E ;

Vardiman, JW ;

Rai, K ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2003, 101 (01) :6-14

← 1 2 3 4 5 6 7 8 9 10 →